Shares of MorphoSys AG (MOR), which have been experiencing strong momentum this year, touched a new 52-week high of $6.85 during intraday trading yesterday.
This global commercial-stage biopharmaceutical company is focused on developing therapies for difficult-to-treat and debilitating types of blood cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com